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Strengths and limitations of this study
 ► Utilisation of the consolidated framework for imple-
mentation research in planning this research will 
facilitate subsequent adaptation and generalisability 
for other programmes implementing evidence-based 
therapies in low/middle-income countries (LMICs).
 ► Collaborative investigation with patient and public 
involvement representatives, experts in the field and 
policymakers in each country to identify the unique 
country or site-specific barriers and facilitators and 
possible implementation strategies to compensate 
for these will help ensure sustainable implementa-
tion of cognitive stimulation therapy (CST).
 ► Valid and reliable outcome measures for each coun-
try will be used, countering the cross-cultural limita-
tions of some existing measures and projects.
 ► Mixed methodology will ensure extensive evalu-
ation of both objective success of implementation 
and the subjective experience of delivering and en-
gaging with CST in each country, which will inform 
implementation.
 ► Analysis of the cost of CST delivery and any financial 
benefits of CST provision by comparing the cost of 
supporting people with dementia pre-CST and post-
CST in each country will inform the sustainability of 
CST in LMICs.
AbStrACt
Introduction In low/middle-income countries (LMICs), the 
prevalence of people diagnosed with dementia is expected 
to increase substantially and treatment options are limited, 
with acetylcholinesterase inhibitors not used as frequently 
as in high-income countries (HICs). Cognitive stimulation 
therapy (CST) is a group-based, brief, non-pharmacological 
intervention for people with dementia that significantly 
improves cognition and quality of life in clinical trials and 
is cost-effective in HIC. However, its implementation in 
other countries is less researched. This protocol describes 
CST-International; an implementation research study of 
CST. The aim of this research is to develop, test, refine and 
disseminate implementation strategies for CST for people 
with mild to moderate dementia in three LMICs: Brazil 
(upper middle-income), India (lower middle-income) and 
Tanzania (low-income).
Methods and analysis Four overlapping phases: (1) 
exploration of barriers to implementation in each country 
using meetings with stakeholders, including clinicians, 
policymakers, people with dementia and their families; (2) 
development of implementation plans for each country; (3) 
evaluation of implementation plans using a study of CST in 
each country (n=50, total n=150). Outcomes will include 
adherence, attendance, acceptability and attrition, agreed 
parameters of success, outcomes (cognition, quality 
of life, activities of daily living) and cost/affordability; 
(4) refinement and dissemination of implementation 
strategies, enabling ongoing pathways to practice which 
address barriers and facilitators to implementation.
Ethics and dissemination Ethical approval has been 
granted for each country. There are no documented 
adverse effects associated with CST and data held will be 
in accordance with relevant legislation. Train the trainer 
models will be developed to increase CST provision in 
each country and policymakers/governmental bodies 
will be continually engaged with to aid successful 
implementation. Findings will be disseminated at 
conferences, in peer-reviewed articles and newsletters, in 
collaboration with Alzheimer’s Disease International, and 
via ongoing engagement with key policymakers.
IntroduCtIon
Dementia is a substantial global challenge 
affecting around 46.8 million people globally, 
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with an estimated annual worldwide cost of 818 billion 
US dollars.1 Currently, there are 27.3 million people with 
dementia in low/middle-income countries (LMICs). 
Between 2015 and 2050, the number of older people living 
in high-income countries (HICs) is forecast to increase by 
56%, compared with 138% in upper middle-income coun-
tries, 185% in lower middle-income countries and 239% 
in low-income countries. There is a major disjunction 
between global distribution of dementia prevalence, with 
58% of cases currently living in LMICs, and costs, with 
87% of globally spending on dementia incurred in HIC. 
In response, the WHO stated that: ‘A sustained global 
effort is thus required to promote action on dementia 
and address the challenges posed… No single country, 
sector or organisation can tackle this alone’2 (p42).
Despite growing numbers of people living with 
dementia, service provision remains limited in many 
world regions. For example, >1.5 million people in Brazil 
may have dementia but only 20% have been diagnosed.3 
While the current government policy of providing free 
high cost medication has benefitted many people with 
dementia, dementia awareness remains limited and no 
formal and validated psychological or social interventions 
are currently offered. In India, around 4.4 million people 
have dementia and this is expected to increase to over 10 
million by 2040.1 Dementia has traditionally been consid-
ered to be a part of normal ageing and not a medical 
problem. This has often resulted in delayed help seeking, 
with an estimated treatment gap of over 90%. Only around 
5% of those with dementia receive a formal diagnosis and 
appropriate treatment, due to a lack of trained profes-
sionals.4 The only dementia prevalence study conducted 
in Tanzania identified an age adjusted prevalence of 6.4% 
in people aged 70 years and over, similar to prevalence in 
many HICs.5 This equates to around 200 000 living with 
dementia nationally, almost all of whom will receive no 
specialist care. While some people will seek treatment 
from traditional healers or alternatives, dementia can be 
associated with high levels of comorbidity, mortality and 
high carer burden.6
In countries where access to medication can be diffi-
cult, non-pharmacological interventions may be an effec-
tive means of treating people with dementia.7 However, 
the evidence base for some non-pharmacological inter-
ventions is variable and, as they are predominantly devel-
oped in HIC,8 they may be less suitable for use in LMICs.
Cognitive stimulation therapy (CST) is a brief, evidence-
based, effective and cost-effective in the UK intervention 
for people with mild to moderate dementia. Developed 
in the UK, it involves 14 sessions over 7 weeks. The aim 
of CST is to improve cognitive function through themed 
group activities, which implicitly stimulate skills including 
memory, executive function and language through tasks 
such as categorisation, word association and discussion 
of current affairs. A Cochrane systematic review of 15 
randomised controlled trials (RCTs) found consistent 
evidence that CST benefits cognition in mild to moderate 
dementia, over and above any medication effects.9 
Furthermore, CST demonstrates the best evidence for 
improving cognitive functioning among all psychosocial 
interventions.10
In the first RCT,11 significant improvements in both 
cognition and quality of life of CST compared with usual 
care (n=201) were documented. A ‘numbers needed to 
treat’ analysis found that improvements in cognition were 
similar to those following use of anticholinesterase inhib-
itors. An economic analysis, in which the cost of running 
CST groups in addition to the differences in use of services 
between the treatment and control groups were calcu-
lated and analysed alongside evidence on cognitive and 
quality of life benefits, found CST to be cost-effective.12 
In 2006, the UK National Institute of Clinical Excellence 
guidance on dementia13 recommended ‘structured group 
Cognitive Stimulation, irrespective of any anti-dementia 
drug prescribed’. It remained the only non-pharmaco-
logical intervention recommended to improve cognition, 
independence and well-being in the updated 2018 guide-
lines.14 A report by the NHS Institute of Innovations and 
Improvements indicated that if CST were widely imple-
mented, it would save the National Health Service (NHS) 
£54.9 million annually through combining healthcare 
cost savings with quality of life improvements.15
Global adaptation and evaluation of CST coincided 
with the World Alzheimer’s Report 2011,16 which stated 
that CST should routinely be given to people with early 
stage dementia and advocated CST as an effective, 
low-cost intervention in developing countries. To ensure 
that CST provision is translated into routine clinical prac-
tice, implementation research that addresses practical 
issues such as referral pathways and barriers to successful 
provision is needed. The aim of the CST-International 
research programme is to develop, test, refine and dissem-
inate implementation strategies for CST for people with 
dementia in three diverse parts of the world. The primary 
objective is to create a sustainable CST implementation 
programme that enhances quality of life and cognition for 
people with dementia. A secondary objective is to increase 
awareness and skills in the detection and management of 
dementia, both for health workers and families.
One upper middle-income (Brazil), one lower-middle 
income (India) and one low-income (Tanzania) country 
have been selected. They have all: (1) begun or completed 
feasibility or pilot work on CST with positive results, with 
two sites previously awarded funding for feasibility work; 
(2) previously translated and adapted the CST manual, 
following the same recommended process17 and (3) 
engaged local stakeholders and gathered initial data on 
implementation.
MEthodS And AnAlySIS
The CST-International team is comprised of both 
national and international staff. The international team 
is co-ordinated in the UK and consists of psychologists, 
psychiatrists and researchers at higher education instu-
tions and NHS trusts. National teams in each country 
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are comprised of psychologists, psychiatrists, physicians, 
nurses, occupational therapists and researchers. National 
teams belong to higher education institutions, non-gov-
ernmental organisations, government healthcare facili-
ties, public and private healthcare facilities.
The methods used was informed by theories and 
frameworks, where the focus is on improved transla-
tion of interventions to routine practice. This enables 
interventions to be sustainable and continue to be used 
following the completion of research trials. The consoli-
dated framework for implementation research (CFIR)18 
is an amalgamation of 19 models of implementation and 
incorporates various theories around innovation, organi-
sational change, implementation, knowledge translation, 
research uptake and dissemination. The CFIR has five 
domains: (1) characteristics of the intervention, (2) the 
outer setting, (3) the inner setting, (4) characteristics of 
individuals and (5) process. These are associated with 39 
further constructs such as the adaptability of the inter-
vention, patient needs and resources, the structural char-
acteristics of the intervention and knowledge and beliefs 
about the intervention.
Phase I: exploring the barriers and facilitators to 
implementation (months 1–6)
The aim of phase I is to identify potential barriers and 
facilitators to implementation of CST in each unique 
context, identifying areas requiring further adaptation. 
Initially, this will be addressed using a systematic review of 
psychological and social intervention research in LMICs. 
The systematic review will be used to investigate the effec-
tiveness of previous interventions and implementation 
barriers and facilitators.
Stakeholder meetings
Phase I includes substantial patient and public involve-
ment (PPI), in which the barriers and facilitators to 
implementation will be discussed in a series of stake-
holder meetings with three diverse groups of stake-
holders. Questions for each group were developed using 
the CFIR18 framework and iterative draft questions were 
discussed in national and international teams before a 
final and standardised version was agreed on. Group 1 
will involve policymakers and discussions will be facili-
tated around barriers to policy implementation. Specific 
issues to be addressed will include awareness of dementia 
and ways of managing it, perceived importance and 
complexity of the issue, available capital and capacity. 
Group 2 will consist of policy implementers who will be 
primarily responsible for facilitating CST groups in their 
own service or setting. This group will explore imple-
mentation issues around training and support required, 
accessibility of the manual in its current form, adaptations 
to the 1 day training model, how people will be recruited 
for CST groups and what degree of psychological and 
educational support and advertising might be needed. 
This group will discuss how stigma, cultural expecta-
tions, age and gender issues, perceived resistance from 
service users and transport barriers might be addressed. 
Group 3 will consist of people with dementia, carers and 
community leaders or village elders where appropriate. 
In this group, knowledge of dementia, stigma, gender 
issues and logistics issues such as transport and meeting 
spaces will be discussed. A minimum of 10 stakeholders 
per group will be used in each country and the research 
team in each country will be responsible for inviting 
stakeholderings to meetings using their existing connex-
ions and exploring new ones. All stakeholder meetings 
will be preceded by introductory talks on both dementia 
and CST. This will ensure that all stakeholders have at 
least a minimum understanding of both. Stakeholders 
will be encouraged to give their opinions on the topics 
discussed and facilitators will ensure that all stake-
holders understand the purpose and requirements of 
the meetings.
Example questions for each stakeholder group include:
 ► Group 1: what, if any, national guidelines regarding 
dementia treatments are available and what guide-
lines should CST be in at the end of this study?
 ► Group 2: what are the known barriers people encounter 
when accessing healthcare services generally?
 ► Group 3: what would make you/your friend or rela-
tive with dementia more likely to attend CST sessions?
Developing ‘implementation mechanisms’
Findings from phase I will be collated for each country 
and a descriptive analysis will be used to document 
both similarities and unique implementation issues 
across countries. National teams will tabulate all iden-
tified barriers and facilitators and, using the CFIR as a 
guide and in consultation with experts in each country, 
propose mechanisms that could be used to overcome 
each barrier or support each facilitator. These will be 
tabulated alongside the barriers and facilitators identi-
fied and proposed mechanisms will be rated according 
to how essential the mechanism is to support implemen-
tation and how difficult the proposed mechanism is to 
execute. In the first instance, ratings will be conducted 
by CST-International staff and investigators in their role 
as experts in their respective countries. Following these 
ratings, an advisory group consisting of a minimum 
of three representatives from each of the stakeholder 
groups will be asked to provide further ratings. The 
resulting matrix of ratings will be assigned numerical 
values and the mode used in order to weight mecha-
nisms on how essential and easy they are to use. The 
results of this will be discussed in local teams where 
members will be asked to reach a consensus and justify 
which mechanisms are to be used.
Phase II: development of implementation strategies (months 
7–10)
The aims of phase II are to generate implementation 
plans ready to be tested in phase III, and to complete 
preparation work required, including adaptation to the 
training protocol and generating recruitment sources.
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Agreeing an ‘implementation plan’
Data from phase I will be organised into country specific 
implementation plans and a local co-ordinator in each 
site will be responsible for writing this plan. The local 
co-ordinator will be a member of the national research 
team and be supervised by a site or country lead. Each 
plan will include written summaries of the implemen-
tation mechanisms to be used and the justification for 
doing so, with reference to available time and resources. 
The local co-ordinator will also agree action plans with 
individual investigators, in which specific mechanisms 
are assigned to members of staff to execute. Each plan 
will be circulated and approved by the key team (coappli-
cants, collaborators, advisory groups and PPI groups). A 
consensus meeting in London, UK, which lead coappli-
cants from each country will attend, will be used to refine 
implementation plans in each country.
Additional implementation activities
To ensure customised, country specific implementation, 
other tasks will be undertaken. First, adaptations to the 
1 day CST training course will be considered. Training 
modules include the biopsychosocial model of dementia, 
screening using outcome measures of cognition, mood 
and quality of life. Second, researchers will prepare a 
cascade model of training to be used in phases III and 
IV. Third, a 3 hour dementia awareness course for people 
with dementia, carers and members of the general public 
will be developed. This course will be based on the 
successful 10/66 carer training intervention,19 previous 
research in each country20 21 and the CST training course. 
Fourth, further supplementary support needed for imple-
mentation will be considered. For example, nurses previ-
ously conducted physical examinations including blood 
pressure checks in Tanzania and India to help normalise 
the process of attending CST sessions. Fifth, psychoed-
ucation, dissemination and advertising routes will be 
considered, with the overall aim being to generate appro-
priate referral routes. Previously, this was accomplished 
in Tanzania through screening days organised by reli-
gious leaders and village elders. Finally, staff will iden-
tify the resources needed to support implementation, 
for example, identifying recruiting sites, facilitators and 
room space in order to run CST sessions.
Phase III: testing the implementation strategy with a study of 
CSt (months 11–28)
The aims of phase III are to evaluate the feasibility of 
implementation strategies for each country. This will be 
accomplished using a study of CST where the following 
outcomes will be assessed: (1) adherence, attendance, 
acceptability and attrition, (2) number of trained facili-
tators and number of groups run, (3) the effectiveness of 
CST on outcomes of cognition and quality of life and (4) 
costs and the affordability of the intervention.
During phase III, CST facilitators will be trained to 
deliver CST using materials developed in previous phases. 
A minimum of eight CST groups in each country will 
also be established, recruiting 50 people with dementia 
in each country. Thus, the total sample size will be 150 
people with dementia. The sample size was calculated 
pragmatically, based on discussions with each team 
regarding their available time, resources and the sample 
size required to evaluate the success of implementa-
tion strategies. To maximise recruitment, we will ensure 
that recruitment strategies target a range of healthcare 
settings and services including both private and public 
systems where appropriate. For example, primary health 
clinics and privately run day centres. National teams will 
be responsible for contacting these sites, using the most 
appropriate means. This may be through formal letters or 
email and teams will meet managers or leaders to explain 
the study in detail prior to their recruitment.
Screening and inclusion criteria
The second version of the Mental Health Gap action 
programme (WHO),22 which has a module on dementia, 
will be used by doctors, nurses and health workers to 
generate a list of suspected cases of dementia in the 
community. In India and Brazil, identified cases will be 
screened using the community screening instrument for 
dementia CSI-D brief.23 This contains seven cognitive 
items and six informant items, taking <5 min to admin-
ister. In Tanzania, this will be replaced by the IDEA cogni-
tive screen24; a six-item cognitive screen, which includes 
items from the CSI-D and the consortium to establish 
a registry for Alzheimer’s disease 10 word list. It also 
contains an added matchstick task in place of the shape 
copying task, which has been validated in Nigeria. The 
screen has better reliability and validity in Tanzania, with a 
sensitivity of 84.6% and specificity of 89.1%. All suspected 
cases will be checked against International Classification 
of Diseases, 10th revision (ICD-10) criteria25 for dementia. 
All screeners have previously been trained to use these 
tools and screening will take place in the most appro-
priate venue for each country. For example, a recently 
established memory clinic will be used for screening in 
Tanzania. Screening for CST will continue until the spec-
ified sample size for each country is reached.
The inclusion criteria have been informed by previous 
research but have been adapted to meet local needs. To 
be included, participants must:
1. Meet the ICD-10 criteria for dementia, as assessed by a 
trained clinician.
2. Be rated as having mild to moderate dementia on the 
Clinical Dementia Rating Scale.26
3. Have sufficient hearing and vision to follow conversa-
tion/comment on visual material.
4. Have the ability to participate in a group for 1 hour.
5. Be willing and able to complete measures of cognition 
and quality of life.
6. Be willing and able to travel to a group.
Outcomes
Sociodemographic information collected will include 
age, gender, dementia subtype (if known), level of 
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Table 1 Phase III outcome measures
Domain Measure Items Rater Details
Cognition Alzheimer’s Disease 
Assessment Scale—
Cognitive Subscale 
(ADAS-Cog)32
21 Person 
living with 
dementia 
(PwD)
Internationally recognised measure that includes 
three subscales: language, memory/new learning 
and praxis. It has been extensively validated in a 
range of settings and been adapted for use in in 
Sub-Saharan Africa as the main cognitive outcome 
in the IDEA study.33 This research is currently 
guiding adaptation work in India.
Quality of life WHO Quality of Life- 
Bref (WHOQOL-BREF)34
26 PwD Consists of four domains: physical, psychological, 
social and environmental. Internal consistency for 
all domains is acceptable (α=>0.7) and the tool has 
been extensively validated across LMICs.35 Raw 
scores will be recorded (4–20), as per WHOQOL-
Bref protocol.
Activities of daily living 
(ADLs)
EASY-Care 
Independence Scale 
(EASY-Care)36
18 PwD Developed from existing measures of ADLs, the 
measure uses a weighting system to measure 
dressing, bathing, housework, preparing meals 
and feeding. Total scores range from 0 to 100, 
with higher scores denoting greater degree of 
dependence. It has been validated in LMIC’s, most 
recently in India where internal consistency was 
reported as excellent.
Burden Zarit Burden Interview 
(ZBI)37
22 Caregiver Rates the impact of a person’s disabilities on the 
caregivers’ life. Responses are rated from 0 to 
4, with higher scores indicating greater burden. 
Internal consistency is excellent (α=0.92), however, 
despite some validation in LMICs including India,38 
there is some evidence to suggest it is not cross-
culturally valid.
Dementia Caregiver 
Experience Scale 
(DemCarES)39
17 Caregiver Due to potential issues with the ZBI, the DemCarES 
will also be utilised to assess caregiver burden. The 
CES was developed recently in India to account for 
the unusually low levels of burden documented by 
existing measures. Internal consistency has been 
found to be excellent (α=0.91) and the measure will 
be translated according to best practice and piloted 
in each of the countries.
Cost-affordability Client Services Receipt 
Inventory (CSRI)40
N/A Caregiver The CSRI is used to collect information on service 
utilisation, income, accommodation and other cost-
related variables. It has five sections consisting 
of: background information, accommodation and 
living situation, employment history, earnings and 
benefits, a record of services used and information 
about unpaid carers. Country-specific CSRIs will be 
used or developed over the course of the project.
Resource Utilisation in 
Dementia (RUD)41
N/A Caregiver The RUD is designed for the collection of data 
pertaining to formal and informal care resource 
use across different countries and care systems. 
It includes items on accommodation, time spent 
assisting with activities of daily living and time spent 
assisting with instrumental activities of daily living.
LMICs, low/middle-income countries.
literacy and education, ethnicity, previous or lifetime 
occupation, family composition and caregiver availability 
and arrangements. The same instruments will be used 
across sites (table 1), to facilitate cross-cultural compar-
isons and statistical analyses. Outcomes measures will 
be administered by trained research assistants at base-
line (week prior to commencing CST) and follow-up 
(week following completion of CST). The study of CST is 
primarily to assess the effectiveness of the implementation 
strategies developed and is not powered for statistically 
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Figure 1 Phase III participant flow. CST, cognitivestimulation 
therapy.
significant change. The main goal of the outcomes is to: 
(a) provide an indication of any improvements following 
CST and (b) demonstrate good practice through gath-
ering outcome data. Outcome measures listed in table 1 
have been translated, adapted and culturally validated for 
each setting. Adaptations to the Client Services Receipt 
Inventory and the Resource Utilisation in Dementia for 
each country are ongoing and will follow a standard oper-
ating procedure previously established. Any amendments 
to outcome measures will be informed by phases I and II 
of the project.
Intervention
All participants who meet inclusion criteria and complete 
baseline assessments will receive 14 sessions of CST over 
7 weeks (figure 1). The previously established and tested 
adaptions of the CST manual for each country will be 
followed. Examples of adapted activities include the 
‘current affairs’ session in Tanzania including village news 
and events as there is limited awareness of national news. 
In Brazil, given its continental size; the orientation session 
will rely on local instead of national maps. In India, as 
older men would not traditionally be involved in cooking, 
the food session included budgeting for a meal. Task 
adaptation to accommodate illiteracy and uncorrected 
sensory impairment and use of locally available materials 
and equipment to ensure sustainability, will be essential 
in all places. Particularly in Tanzania and India, care will 
be needed to select a meeting place acceptable to all (eg, 
avoiding using a place of worship for groups of mixed reli-
gion). Two sessions may need to be held on the same day, 
to reduce travel time, with informal time before sessions 
to allow for traffic delays. Speicific venues for CST will be 
explored and recruited using our implementation strate-
gies in phase II. However, we aim to recruit in two or more 
regions of each country, including Rio de Janeiro and Sao 
Paulo in Brazil; Chennai, Mysuru, Kerala and New Delhi 
in India; Kilimanjaro and Arusha in Tanzania. Groups will 
take place in both rural and urban settings which include 
outpatient units, carers associations, Primary Health Care 
Centres and community settings.
A 3 hour family educational session will be offered by 
the researchers to all families of those who were screened 
and not included in the study, and to those who partic-
ipate after completion of CST and follow-up outcome 
measures. The aim of this course will be to increase aware-
ness of dementia in each country and will be developed 
based on findings in phase II. In addition, the course will 
contain information designed to combat common barriers 
across countries such as knowledge and awareness of both 
dementia and dementia treatments. Wherever possible, 
the course will be offered in a group format, both to 
encourage communication between family members and 
for the economy of time. People may be offered further 
support such as physical examinations, depending on the 
setting, needs and availability of resources.
Qualitative interviews
In each country, qualitative interviews will be conducted 
after completion of CST, with equal numbers of service-
users (people with dementia and their families), profes-
sionals training or facilitating CST and policymakers. 
Recruitment will continue until data saturation has been 
reached. Based on previous qualitative studies of CST, it 
is anticipated that ~15–20 interviews will be conducted 
in each country. Interview schedules will be developed 
and guided by the 39 items of the CFIR, with questions 
about feasibility, effects and implementation of CST 
directed to each stakeholder group. The aim of this is to 
further evaluate the implementation strategies utilised 
over the course of the grant including strengths, weak-
nesses, support needed and wider acceptability of the 
programme for the public, health professionals and polit-
ically. Narrative interviewing,27 which focuses on lived 
experiences with minimal coaching or directing from the 
interviewer will be used by trained qualitative researchers 
in each site, who will also code and analyse results.
Feasibility analysis will consist of:
1. Recruitment, including people who were approached, 
agreed to attend, refused (and reasons for this) and 
met inclusion criteria.
2. Attrition, with details of numbers of those dropping out 
and reasons given for this. Twenty per cent (or less) 
attrition is generally considered acceptable.28
3. Attendance, average number of sessions and reasons for 
non-attendance.
4. Acceptability of outcome measures, examining whether 
completion was possible and missing data.
5. Adverse events and side-effects, routinely recorded accord-
ing to ethical procedures.
6. Adherence to manual. This will enable us to assess wheth-
er people are delivering CST according to the proto-
col. People will be given a brief checklist to complete 
after each session, developed as part of the mainte-
nance CST trial.29
Agreed parameters of success for the study of CST will consist 
of:
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1. Number of people trained to deliver CST and number 
of people trained as CST trainers.
2. Number of groups run.
3. Total number receiving CST across settings and 
countries.
Outcome measure and qualitative analysis
Analysis of outcome data will include descriptive (eg, 
mean, median, frequency) and inferential (eg, paired 
t-test, Wilcoxon signed-ranks test, percentage change) 
statistics using the Statistical Package for Social Sciences. 
Analysis of variance analyses with time as a within-sub-
jects factor and group (CST vs treatment as usual) as a 
between-subjects factor will also be used, where appro-
priate . Data will be primarily presented for each site 
separately, with between-site comparisons made as appro-
priate. Data will be combined for analysis where this is 
justified, and it is meaningful to do so. Qualitative inter-
views will be audio recorded, transcribed, translated and 
analysed manually using interpretive phenomenological 
analysis,30 which has been adapted and validated for use 
in LMIC settings, for development of key themes. Tran-
scripts will be revisited for accuracy and consistency by 
bilingual investigators raising data trustworthiness. Trian-
gulating quantitative, qualitative and narrative data, find-
ings across settings and within and between countries 
will be compared. The aim of this is to identify common 
themes for CST provision as well as geographical and 
cultural variations.
Economic analysis
We will collect data on direct and indirect costs including 
the cost of delivering CST in each setting, use of services 
by people with dementia and caregivers, and on the time 
spent by caregivers in supporting people with dementia. 
We will attach country-specific unit costs to services. Incre-
mental cost-effectiveness ratios will be computed, based 
on the (uncontrolled) pre–post design. This analysis will 
be conducted across the three countries by a team at the 
London School of Economics and Political Science.
Phase IV: pathways to practice (months 29–36)
The aim of phase IV is to establish a model of good prac-
tice and a scalable plan, outlining ongoing and sustain-
able CST provision. We will engage with policymakers 
including utilising support obtained from Alzheimer 
Disease International (ADI), as part of a symposium at 
their international conferences. We will also examine key 
outcomes from the study of CST in phase III, in order to 
support the translation of CST into clinical practice for 
each country.
Ensuring ongoing recruitment to CST groups
Through examining patterns of refusal, attendance, attri-
tion and experience of CST from qualitative interviews, 
we will consider ways to counter this including psychoed-
ucation to reduce stigma or providing increased support 
for transport. We will consider whether the inclusion/
exclusion criteria were appropriate and adapt them if 
needed. We will also create a sustainable system for CST 
groups following the completion of this research. This 
will require involvement of ongoing networks and finan-
cial agreements.
Dissemination
We will examine the number of people trained, the 
quantum of required support and recommend sustain-
able training models including ‘train the trainer’ 
concepts. We will engage with universities and other 
course providers with the view of introducing CST into 
professional and vocational courses such as nursing, occu-
pational therapy (OT), psychology, geriatric counsellors 
and care providers. This has been successful in Tanzania 
where CST is now taught routinely to undergraduate OT 
students at Kilimanjaro Christian Medical College. By the 
end of this study, we aim to have several people trained 
as CST trainers in different regions in each country, with 
clear plans about cascading this nationally. In remote 
communities in Tanzania, we will train primary health-
care workers with support and training from OT, so that 
groups can take place during the rainy season when access 
may be impossible for health workers from local towns.
We will refine and publish the adapted CST training 
manuals for each country. The availability of the manual 
and training infrastructure will be tailored for the needs 
and resources of each site. However, the rights to the 
CST manual in each country have been secured from the 
publishers.
Results of each phase of the trial will be disseminated at 
international conferences. Support for the current grant 
has been obtained by ADI, who will provide ongoing 
support including dissemination through newsletters and 
through a symposium at an ADI conference. A series of 
articles from each phase will also be submitted to high 
impact, peer-reviewed journals. Priority will be given to 
journals that specialise in research in lower/middle-in-
come countries. Papers will include a systematic review of 
psychological and social interventions in LMICs, a report 
on the barriers to and facilitators of implementation in 
the different countries, results from the CST study and 
the qualitative interviews.
Recommendation for routine outcome measures
To ensure that any beneficial effect of CST is docu-
mented, the psychometric properties of the measures will 
be assessed, including the ability to detect change and 
whether this change is supported by qualitative data gath-
ered. We will assess whether they were appropriate for 
the setting and population to inform outcomes recom-
mended for routine practice.
Costs/affordability of models
We will: (1) examine the cost and potential affordability 
of CST; (2) calculate the total costs of supporting people 
with dementia pre-CST and post-CST; (3) investigate 
the cost-effectiveness of CST in each country from soci-
etal and health system perspectives and (4) appraise 
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the affordability of CST in consultation with local 
stakeholders.
data management plan
Data will be collected and analysed by researchers in 
each site, adhering to relevant data protection legisla-
tion for each country. All researchers have previously 
been trained for data handling and all electronic data 
will be stored on secure servers with inbuilt data encryp-
tion, automated back-up and anti-virus protection. Hard 
copies of data will be kept securely, in a locked cabinet 
and will be stored according to each institutions record 
retention policy. All data will be pseudonymised using a 
participant key and, to ensure that they comply with UK 
data protection legislation, UK sites will never have access 
to this key, rendering data anonymised. Anonymised data 
will be kept in line with University College London’s 
(UCL) record retention policy.
Study management and co-ordination
CST-International is sponsored by UCL. The programme 
manager (CS) from UCL will co-ordinate all work 
between three countries, support the researchers at each 
site, co-ordinate network meetings, assist with analysis 
of data and oversee any publications. Local teams will 
have monthly meetings with CS and AS using software 
such as Skype where tasks for the coming month will be 
discussed and decided on, with clear action points for 
each member of staff. Any operational difficulties will be 
discussed during team meetings, with advice sought from 
the appropriate institution where necessary. Representa-
tives from each country will also meet annually in person 
to facilitate peer learning across countries.
An independent Advisory Group has been established 
and will meet once a year. Members include a represen-
tative from ADI, experts in CST, epidemiologists special-
ising in LMICs, a person living with dementia and a carer. 
The Advisory Group will advise the programme manager 
on all aspects of the research programme including meth-
odology, dissemination and public engagement.
Ethical considerations and approval
People with dementia will be included in this programme 
of work, both as PPI representatives and as participants in 
phase III. No personal information will be sought from 
PPI representatives. For phase III, people with dementia 
will be required to provide informed consent. To ensure 
capacity to consent, established screening procedures20 31 
in each country will be followed. CST has no documented 
adverse effects and, therefore, risk to participants will be 
low. Consent will be treated as an ongoing process and 
reaffirmation of consent will be sought at each partic-
ipant contact. All participants and caregivers where 
appropriate will be provided with accessible information 
regarding phase III of the work and will be required to 
sign a consent form if they take part. Should participants 
be unable to write, thumb prints will be taken instead. 
Identifiable information will be held securely and 
separately from research data in each country and will be 
deleted following completion of the project. Anonymised 
data will be transferred to the UK for analysis.
Patient and public involvement
PPI will form an integral part of the research and repre-
sentatives will be involved from phase I through to phase 
IV. As part of phase I, PPI representatives will be enlisted 
to codevelop implementation strategies for CST and, as 
part of phase IV, will help to implement these strategies 
across the three countries.
Author affiliations
1Research Department of Clinical, Educational and Health Psychology, University 
College London (UCL), London, UK
2Department of Psychiatry, Centre of Excellence in Mental Health, Postgraduate 
Institute of Medical Education and Research (PGIMER) and Dr Ram Manohar Lohia 
Hospital, New Delhi, India
3Dementia Care, Schizophrenia Research Foundation (SCARF), Chennai, India
4Department of Research, Foundation for Research and Advocacy in Mental Health 
(FRAMe), Mysore, India
5Personal Social Services Research Unit (PSSRU), London School of Economics and 
Political Science (LSE), London, UK
6North Tyneside General Hospital, Northumbria Healthcare NHS Foundation Trust, 
North Shields, UK
7Institute for Health and Society, Newcastle University, Newcastle upon Tyne, UK
8Postgraduate Program of the Psychobiology Department, Universidade Federal de 
Sao Paulo, São Paulo, Brazil
9Institute of Psychiatry, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 
Brazil
10Department of Psychology, PUC-Rio, Rio de Janeiro, Brazil
11Institute of Psychiatry, King's College London, London, UK
12Institute of Mental Health, University of Nottingham, Nottingham, UK
13Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
14Department of Psychiatry, Government Medical College, Kerala, India
15Department of Research, Schizophrenia Research Fondation (SCARF), Chennai, 
India
Contributors AS conceived the research, was primarily responsible for writing 
the protocol and acts as Chief Investigator for CST-International. CRS assisted 
in the writing of the protocol, costed the grant and prepared this manuscript for 
submission. CRS is the Programme Manager for CST-International. MC, SV, MKr, 
SKS and TR are the India coapplicants and researchers who assisted in developing 
the methodology for the proposal and writing the protocol. BD from the Mysore site 
contributed to the protocol. DCM, JL and CF are the Brazil leads and assisted in 
the writing of the protocol. RW, S-MP and CD are the Tanzania leads and assisted 
with the writing of the protocol. MWO and SM are UK based coapplicants, who 
commented on the protocol. AC-H and MKn provided information for the economic 
analysis of CST.
Funding This work is supported by the following Global Alliance for Chronic 
Diseases (GACD) funding agencies: The United Kingdom Medical Research 
Council (MRC: MR/S004009/1) and the Indian Council of Medical Research (ICMR: 
Indo-foreign/67/M/2018-NCD-I). No funding bodies were involved in the design, 
collection, analysis, interpretation or writing of the research or manuscript.
disclaimer The views expressed are those of the authors and not necessarily 
those of GACD, the MRC or ICMR.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval Ethical approval was granted by the relevant body in each 
country. In Brazil, an ethics amendment was granted by the Federal University 
of Rio de Janeiro Institute of Psychiatry REC (ref: 57019616.5.0000.5263) to 
incorporate the current research programme. In India, approval was granted by 
Institutional Ethics Committees (IECs) in each of the four sites (Schizophrenia 
Research Foundation; SCARF: Chennai; 28 November 2017, Government Medical 
College: Thrissur; B6-8772/2016/MCTCR, PGIMER Dr RML Hospital: New Delhi; 
219(38/2017)/IEC/PGIMER/RMLH43, All India Institute of Speech and Hearing: 
 o
n
 August 21, 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030933 on 20 August 2019. Downloaded from 
9Spector A, et al. BMJ Open 2019;9:e030933. doi:10.1136/bmjopen-2019-030933
Open access
Mysuru; SH/Extramural/1/2017–18). In Tanzania, approval was granted by KCMC 
and nationally by the National Institute of Medical Research, Dar-es-Salaam.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
rEFErEnCES
 1. Alzheimer's Disease International (ADI). World Alzheimer report 
2015: the global impact of dementia. London: Alzheimer's Disease 
International (ADI), 2015.
 2. World Health Organisation (WHO). First WHO Ministerial conference 
on global action against dementia. Geneva: WHO, 2015.
 3. Nakamura AE, Opaleye D, Tani G, et al. Dementia underdiagnosis in 
Brazil. Lancet 2015;385:418–9.
 4. Prince M, Livingston G, Katona C. Mental health care for the 
elderly in low-income countries: a health systems approach. World 
Psychiatry 2007;6:5–13.
 5. Longdon AR, Paddick S-M, Kisoli A, et al. The prevalence of 
dementia in rural Tanzania: a cross-sectional community-based 
study. Int J Geriatr Psychiatry 2013;28:728–37.
 6. Kisoli A, Gray WK, Dotchin CL, et al. Levels of functional disability 
in elderly people in Tanzania with dementia, stroke and Parkinson's 
disease. Acta Neuropsychiatr 2015;27:206–12.
 7. Alzheimer's Disease International (ADI). World Alzheimer report 2016: 
improving healthcare for people living with dementia; coverage, 
quality and costs now and in the future. London: Alzheimer's Disease 
International (ADI), 2016.
 8. McDermott O, Charlesworth G, Hogervorst E, et al. Psychosocial 
interventions for people with dementia: a synthesis of systematic 
reviews. Aging Ment Health 2019;23:393–403.
 9. Woods B, Aguirre E, Spector AE, et al. Cognitive stimulation to 
improve cognitive functioning in people with dementia. Cochrane 
Database Syst Rev 2012;(2):CD005562.
 10. Olazarán J, Reisberg B, Clare L, et al. Nonpharmacological therapies 
in Alzheimer's disease: a systematic review of efficacy. Dement 
Geriatr Cogn Disord 2010;30:161–78.
 11. Spector A, Thorgrimsen L, Woods B, et al. Efficacy of an evidence-
based cognitive stimulation therapy programme for people 
with dementia: randomised controlled trial. Br J Psychiatry 
2003;183:248–54.
 12. Knapp M, Thorgrimsen L, Patel A, et al. Cognitive stimulation therapy 
for people with dementia: cost-effectiveness analysis. Br J Psychiatry 
2006;188:574–80.
 13. National Institute for Health and Care Excellence (NICE). Dementia: 
supporting people with dementia and their carers in health and social 
care. London: NICE, 2006.
 14. National Institute for Health and Care Excellence (NICE). Dementia: 
assessment, management and support for people living with 
dementia and their carers. London: NICE, 2018.
 15. Matrix Evidence. An economic evaluation of alternatives to 
antipsychotic drugs for individuals living with dementia. Coventry: 
National Health Service (NHS) Institute for Innovation and 
Improvement, 2011.
 16. Alzheimer's Disease International (ADI). World Alzheimer report 2011: 
the benefits of early diagnosis and intervention. London: International 
Alzheimer's Disease (ADI), 2011.
 17. Aguirre E, Spector A, Orrell M. Guidelines for adapting 
cognitive stimulation therapy to other cultures. Clin Interv Aging 
2014;9:1003–7.
 18. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation 
of health services research findings into practice: a consolidated 
framework for advancing implementation science. Implement Sci 
2009;4:50.
 19. Alzheimer's Disease International (ADI). 10/66 dementia research 
group: helping carers to care trainers manual. London: ADI, 2009.
 20. Paddick S-M, Mkenda S, Mbowe G, et al. Cognitive stimulation 
therapy as a sustainable intervention for dementia in sub-Saharan 
Africa: feasibility and clinical efficacy using a stepped-wedge design. 
Int Psychogeriatr 2017;29:979–89.
 21. Mkenda S, Olakehinde O, Mbowe G, et al. Cognitive stimulation 
therapy as a low-resource intervention for dementia in sub-Saharan 
Africa (CST-SSA): adaptation for rural Tanzania and Nigeria. Dementia 
2018;17:515–30.
 22. World Health Organisation (WHO). WHO mental health gap action 
(mhGAP). Geneva: WHO, 2014.
 23. Prince M, Acosta D, Ferri CP, et al. A brief dementia screener suitable 
for use by non-specialists in resource poor settings--the cross-
cultural derivation and validation of the brief Community Screening 
Instrument for Dementia. Int J Geriatr Psychiatry 2011;26:899–907.
 24. Paddick S-M, Gray WK, Ogunjimi L, et al. Validation of the 
identification and intervention for dementia in elderly Africans (idea) 
cognitive screen in Nigeria and Tanzania. BMC Geriatr 2015;15:53.
 25. World Health Organisation (WHO). The ICD-10 classification of 
mental and behavioural disorders: diagnostic criteria for research. 
Geneva: WHO, 1993.
 26. Morris JC. The clinical dementia rating (CDR): current version and 
scoring rules. Neurology 1993;43:2412–4.
 27. Biggerstaff D, Thompson AR. Interpretative phenomenological 
analysis (IPA): a qualitative methodology of choice in healthcare 
research. Qual Res Psychol 2008;5:214–24.
 28. Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in 
randomised controlled trials. BMJ 2006;332:969–71.
 29. Orrell M, Aguirre E, Spector A, et al. Maintenance cognitive 
stimulation therapy for dementia: single-blind, multicentre, pragmatic 
randomised controlled trial. Br J Psychiatry 2014;204:454–61.
 30. Smith JA, Flowers P, Larkin M. Interpretative phenomenological 
analysis: theory, method and research. London: Sage, 2009.
 31. Indian Council of Medical Research (ICMR). National ethical 
guidelines for biomedical and health Presearch involving human 
participants. New Delhi, India: Indian Council of Medical Research 
(ICMR), 2017.
 32. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's 
disease. Am J Psychiatry 1984;141:1356–64.
 33. Paddick S-M, Kisoli A, Mkenda S, et al. Adaptation and validation of 
the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) 
in a low-literacy setting in sub-Saharan Africa. Acta Neuropsychiatr 
2017;29:244–51.
 34. Skevington SM, Lotfy M, O'Connell KA, et al. The world Health 
organization's WHOQOL-BREF quality of life assessment: 
psychometric properties and results of the International field trial. A 
report from the WHOQOL group. Qual Life Res 2004;13:299–310.
 35. Silva PAB, Soares SM, Santos JFG, et al. Cut-Off point for 
WHOQOL-bref as a measure of quality of life of older adults. Rev 
Saúde Pública 2014;48:390–7.
 36. Jotheeswaran AT, Dias A, Philp I, et al. Calibrating EASY-
Care independence scale to improve accuracy. Age Ageing 
2016;45:890–3.
 37. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the 
impaired elderly: correlates of feelings of burden. Gerontologist 
1980;20:649–55.
 38. Brinda EM, Rajkumar AP, Enemark U, et al. Cost and burden of 
informal caregiving of dependent older people in a rural Indian 
community. BMC Health Serv Res 2014;14:207.
 39. Vaitheswaran S, Shaji KS, Pandey N, et al. DemCarES - Dementia 
Caregivers Experience Schedule: A psychometric tool to measure 
experience among caregivers of persons with dementia in India. In 
Press.
 40. Beecham E, Candy B, Howard R, et al. Pharmacological 
interventions for pain in children and adolescents with life-limiting 
conditions. Cochrane Database Syst Rev 2015;382:CD010750.
 41. Wimo A, Wetterholm AL, Mastey V, et al. Evaluation of the resource 
utilization and caregiver time in anti-dementia drug trials: A 
quantitative battery. In: Wimo A, Karlsson G, Jonsson B, et al, eds. 
The health economics of dementia. London: Wiley, 1998: 465–99.
 o
n
 August 21, 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030933 on 20 August 2019. Downloaded from 
